Vaccine boosts Chemo-Radiation against cervical cancer in early trial
NCT ID NCT04580771
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests whether adding an experimental vaccine (PDS0101) to standard chemoradiation is safe and helps control advanced cervical cancer. The vaccine trains the immune system to attack HPV-infected tumor cells. About 22 adults with stage IB3-IVA cervical cancer will receive the combination and be monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IB3 CERVICAL CANCER FIGO 2018 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.